A physician is evaluating a 46-year-old man during a routine wellness examination. The patient's past medical history is significant for pancolonic ulcerative colitis diagnosed 12 years ago. His gastrointestinal disease is currently in deep clinical remission, maintained solely on scheduled infliximab infusions. He reports smoking one pack of cigarettes daily for the past 25 years. Due to a prolonged period of uninsurance, he has not undergone any preventive health screenings or received any immunizations over the past decade. Today, he feels well and reports no acute symptoms. Which of the following preventive interventions are indicated for this patient? (Select all that apply)
- 20-valent pneumococcal conjugate vaccineAnswer
- Recombinant zoster vaccineAnswer
- CLow-dose computed tomography of the chest
- DFecal immunochemical testing
- EMeasles, mumps, and rubella vaccine
Answer
The indicated interventions are the 20-valent pneumococcal conjugate vaccine and the recombinant zoster vaccine.
This patient is immunocompromised due to maintenance infliximab (a TNF-alpha inhibitor) therapy for ulcerative colitis. Based on current guidelines, the recombinant zoster vaccine is recommended for all adults aged 19 years and older who are or will be immunodeficient or immunosuppressed. Additionally, adults aged 19 to 64 years with immunocompromising conditions require pneumococcal vaccination; the single-dose 20-valent pneumococcal conjugate vaccine (PCV20) is an indicated option for those with no prior pneumococcal vaccination history. Both of these vaccines are inactivated or recombinant and are safe to administer to patients on biologic therapy.
Step-by-Step Solution
Key Concept
Adults on immunosuppressive therapies require specific vaccinations (e.g., PCV20, RZV) starting at age 19 while strictly avoiding live vaccines, and high-risk disease states (like long-standing IBD) alter standard cancer screening modalities.